Published in Proc Natl Acad Sci U S A on December 31, 2012
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A (2013) 1.77
Potential applications for biguanides in oncology. J Clin Invest (2013) 1.63
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.33
AMPK at the nexus of energetics and aging. Cell Metab (2014) 1.28
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS One (2014) 1.13
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One (2013) 1.06
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol (2014) 1.02
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia (2013) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (2013) 0.99
MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun (2015) 0.99
Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK. EMBO J (2014) 0.97
Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget (2015) 0.96
Breast cancer stem cells. Front Physiol (2013) 0.95
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest (2014) 0.94
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer. Cancers (Basel) (2015) 0.93
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol (2014) 0.93
Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med (2014) 0.93
Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer. Oncogenesis (2015) 0.93
Diabetes, pancreatic cancer, and metformin therapy. Front Physiol (2014) 0.92
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene (2015) 0.92
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol (2013) 0.92
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS One (2014) 0.92
Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience (2014) 0.91
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis (2015) 0.91
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS One (2015) 0.91
Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget (2014) 0.89
Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PLoS One (2015) 0.89
Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int (2015) 0.87
Targeting the LKB1 tumor suppressor. Curr Drug Targets (2014) 0.87
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
Metformin: a case of divide and conquer. Breast Cancer Res (2013) 0.84
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle (2014) 0.84
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci (2015) 0.84
Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol (2015) 0.83
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. Cancer Prev Res (Phila) (2015) 0.82
Metformin Synergistically Enhances Cisplatin-Induced Cytotoxicity in Esophageal Squamous Cancer Cells under Glucose-Deprivation Conditions. Biomed Res Int (2016) 0.82
Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies. J Cardiovasc Pharmacol (2014) 0.82
Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells (2015) 0.82
Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. Oncotarget (2015) 0.82
Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nat Commun (2015) 0.82
Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle (2015) 0.81
Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells. Oncotarget (2015) 0.81
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget (2016) 0.81
Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. Sci Rep (2015) 0.81
Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget (2014) 0.81
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget (2015) 0.81
Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2015) 0.80
Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget (2015) 0.80
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Front Cell Dev Biol (2017) 0.80
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed Res Int (2014) 0.79
In Vitro Anti-Echinococcal and Metabolic Effects of Metformin Involve Activation of AMP-Activated Protein Kinase in Larval Stages of Echinococcus granulosus. PLoS One (2015) 0.79
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids. J Diabetes Res (2015) 0.79
Cancer stem cells: a systems biology view of their role in prognosis and therapy. Anticancer Drugs (2014) 0.79
Liver kinase B1 suppresses lipopolysaccharide-induced nuclear factor κB (NF-κB) activation in macrophages. J Biol Chem (2014) 0.78
Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment. Breast Cancer (Auckl) (2015) 0.78
Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis (2017) 0.78
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer. Biomed Res Int (2015) 0.78
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res (2015) 0.78
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep (2015) 0.78
Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer. J Cancer (2016) 0.78
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Mol Med Rep (2016) 0.78
Homeostatic Signaling by Cell-Cell Junctions and Its Dysregulation during Cancer Progression. J Clin Med (2016) 0.77
Blockage of TGFβ-SMAD2 by demethylation-activated miR-148a is involved in caffeic acid-induced inhibition of cancer stem cell-like properties in vitro and in vivo. FEBS Open Bio (2015) 0.77
Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget (2016) 0.77
Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J Gastroenterol (2014) 0.77
Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. Sci Rep (2016) 0.77
The insights of Let-7 miRNAs in oncogenesis and stem cell potency. J Cell Mol Med (2016) 0.77
The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia (2017) 0.77
Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons. PLoS One (2016) 0.76
Metformin - For the dermatologist. Indian J Pharmacol (2016) 0.76
Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo. Oxid Med Cell Longev (2016) 0.76
Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis. Ther Adv Med Oncol (2017) 0.75
Metformin targets multiple signaling pathways in cancer. Chin J Cancer (2017) 0.75
High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. PLoS One (2017) 0.75
Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt. Int J Mol Med (2015) 0.75
Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase. J Proteome Res (2017) 0.75
Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget (2016) 0.75
Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle. Front Physiol (2016) 0.75
Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget (2016) 0.75
Negative regulation of Bmi-1 by AMPK and implication in cancer progression. Oncotarget (2016) 0.75
Metformin: are potential benefits on cancer risk extended to cancer survival? Oncologist (2013) 0.75
Role of a polyphenol-enriched preparation on chemoprevention of mammary carcinoma through cancer stem cells and inflammatory pathways modulation. J Transl Med (2016) 0.75
A novel double-targeted nondrug delivery system for targeting cancer stem cells. Int J Nanomedicine (2016) 0.75
NHX-5, an Endosomal Na+/H+ Exchanger, Is Associated with Metformin Action. J Biol Chem (2016) 0.75
Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin. J Cancer (2016) 0.75
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. Oncotarget (2016) 0.75
Methylglyoxal as a scavenger for superoxide anion-radical. Dokl Biochem Biophys (2016) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division. Int J Oncol (2017) 0.75
Main constituents of polyphenol complex from seagrasses of the genus Zostera, their antidiabetic properties and mechanisms of action. Exp Ther Med (2017) 0.75
Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov (2017) 0.75
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 7.77
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem (2000) 6.86
Nuclear localization of the C2H2 zinc finger protein Msn2p is regulated by stress and protein kinase A activity. Genes Dev (1998) 6.75
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
Links between metabolism and cancer. Genes Dev (2012) 5.27
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell (2010) 4.02
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell (2010) 3.53
Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 3.42
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett (2007) 2.15
Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr (2007) 2.05
The Warburg effect in 2012. Curr Opin Oncol (2012) 1.54
Nucleocytoplasmic oscillations of the yeast transcription factor Msn2: evidence for periodic PKA activation. Curr Biol (2007) 1.43
An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A (2012) 1.22
Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun (2012) 1.11
Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem (2007) 1.10
Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels (2009) 0.92
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell (2004) 16.15
Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol Cell (2003) 11.78
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
TREX is a conserved complex coupling transcription with messenger RNA export. Nature (2002) 6.53
Intrinsic histone-DNA interactions and low nucleosome density are important for preferential accessibility of promoter regions in yeast. Mol Cell (2005) 6.17
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
Nucleosome positioning signals in genomic DNA. Genome Res (2007) 4.99
Eaf3 chromodomain interaction with methylated H3-K36 links histone deacetylation to Pol II elongation. Mol Cell (2005) 4.77
Intrinsic histone-DNA interactions are not the major determinant of nucleosome positions in vivo. Nat Struct Mol Biol (2009) 4.64
Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell (2006) 4.51
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Evidence for eviction and rapid deposition of histones upon transcriptional elongation by RNA polymerase II. Mol Cell Biol (2004) 4.06
A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell (2010) 4.02
Distinction and relationship between elongation rate and processivity of RNA polymerase II in vivo. Mol Cell (2005) 4.00
Genome-wide location and regulated recruitment of the RSC nucleosome-remodeling complex. Genes Dev (2002) 3.93
The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity (2009) 3.58
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell (2010) 3.53
Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 3.42
Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem (2002) 3.14
Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. Proc Natl Acad Sci U S A (2003) 3.09
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J Biol Chem (2003) 3.08
The FACT complex travels with elongating RNA polymerase II and is important for the fidelity of transcriptional initiation in vivo. Mol Cell Biol (2003) 3.03
A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature (2008) 3.00
Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell (2011) 2.99
The transition between transcriptional initiation and elongation in E. coli is highly variable and often rate limiting. Mol Cell (2006) 2.99
SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature (2012) 2.96
Hog1 kinase converts the Sko1-Cyc8-Tup1 repressor complex into an activator that recruits SAGA and SWI/SNF in response to osmotic stress. Mol Cell (2002) 2.93
Close association of RNA polymerase II and many transcription factors with Pol III genes. Proc Natl Acad Sci U S A (2010) 2.90
A functional evolutionary approach to identify determinants of nucleosome positioning: a unifying model for establishing the genome-wide pattern. Mol Cell (2012) 2.86
Mapping accessible chromatin regions using Sono-Seq. Proc Natl Acad Sci U S A (2009) 2.83
Asf1 mediates histone eviction and deposition during elongation by RNA polymerase II. Mol Cell (2006) 2.71
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal (2009) 2.38
The transcription factor Ifh1 is a key regulator of yeast ribosomal protein genes. Nature (2004) 2.37
Extensive functional overlap between sigma factors in Escherichia coli. Nat Struct Mol Biol (2006) 2.30
A unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol Cell (2004) 2.27
Activator-specific recruitment of Mediator in vivo. Nat Struct Mol Biol (2006) 2.25
Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. Nat Struct Mol Biol (2010) 2.15
Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev (2002) 2.14
Genome-wide occupancy profile of the RNA polymerase III machinery in Saccharomyces cerevisiae reveals loci with incomplete transcription complexes. Mol Cell Biol (2004) 2.13
MAP kinase-mediated stress relief that precedes and regulates the timing of transcriptional induction. Cell (2004) 2.09
Genomic analysis of LexA binding reveals the permissive nature of the Escherichia coli genome and identifies unconventional target sites. Genes Dev (2005) 2.06
Epigenomics: a roadmap, but to where? Science (2008) 1.99
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Cell Biol (2004) 1.98
HBO1 histone acetylase activity is essential for DNA replication licensing and inhibited by Geminin. Mol Cell (2010) 1.95
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A (2010) 1.90
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86
The stress-activated Hog1 kinase is a selective transcriptional elongation factor for genes responding to osmotic stress. Mol Cell (2006) 1.85
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Heterochromatin formation involves changes in histone modifications over multiple cell generations. EMBO J (2005) 1.82
Quantitative sequential chromatin immunoprecipitation, a method for analyzing co-occupancy of proteins at genomic regions in vivo. Nucleic Acids Res (2004) 1.81
Chipper: discovering transcription-factor targets from chromatin immunoprecipitation microarrays using variance stabilization. Genome Biol (2005) 1.80
The transition from transcriptional initiation to elongation. Curr Opin Genet Dev (2008) 1.78
Activator-specific recruitment of TFIID and regulation of ribosomal protein genes in yeast. Mol Cell (2002) 1.76
The Swi/Snf complex is important for histone eviction during transcriptional activation and RNA polymerase II elongation in vivo. Mol Cell Biol (2007) 1.72
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res (2006) 1.71
HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev (2008) 1.67
Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut (2012) 1.65
Genomic studies with Escherichia coli MelR protein: applications of chromatin immunoprecipitation and microarrays. J Bacteriol (2004) 1.65
JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress. Mol Cell (2011) 1.61
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol (2005) 1.58
Eaf3 regulates the global pattern of histone acetylation in Saccharomyces cerevisiae. Mol Cell Biol (2004) 1.56
Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis (2011) 1.49
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res (2011) 1.48
Genomic analysis of protein-DNA interactions in bacteria: insights into transcription and chromosome organization. Mol Microbiol (2007) 1.47
The VP16 activation domain interacts with multiple transcriptional components as determined by protein-protein cross-linking in vivo. J Biol Chem (2002) 1.47
A role for the WWOX gene in prostate cancer. Cancer Res (2006) 1.45
Genomewide identification of Sko1 target promoters reveals a regulatory network that operates in response to osmotic stress in Saccharomyces cerevisiae. Eukaryot Cell (2005) 1.42
MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology (2013) 1.41
An HMG protein, Hmo1, associates with promoters of many ribosomal protein genes and throughout the rRNA gene locus in Saccharomyces cerevisiae. Mol Cell Biol (2006) 1.39
Nucleosome depletion at yeast terminators is not intrinsic and can occur by a transcriptional mechanism linked to 3'-end formation. Proc Natl Acad Sci U S A (2010) 1.37
Cellular stress alters the transcriptional properties of promoter-bound Mot1-TBP complexes. Mol Cell (2004) 1.36
High-throughput sequencing reveals a simple model of nucleosome energetics. Proc Natl Acad Sci U S A (2010) 1.34
Mot1 associates with transcriptionally active promoters and inhibits association of NC2 in Saccharomyces cerevisiae. Mol Cell Biol (2002) 1.34
Where does mediator bind in vivo? PLoS One (2009) 1.33
Epigenetic aberrations during oncogenesis. Cell Mol Life Sci (2011) 1.32
The Cyc8-Tup1 complex inhibits transcription primarily by masking the activation domain of the recruiting protein. Genes Dev (2011) 1.30
MicroRNA Gene Networks in Oncogenesis. Curr Genomics (2009) 1.26
Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology (2011) 1.24
Extensive chromatin fragmentation improves enrichment of protein binding sites in chromatin immunoprecipitation experiments. Nucleic Acids Res (2008) 1.23
Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res (2007) 1.22
An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A (2012) 1.22
Targeted recruitment of Rpd3 histone deacetylase represses transcription by inhibiting recruitment of Swi/Snf, SAGA, and TATA binding protein. Mol Cell Biol (2002) 1.22
Rank-statistics based enrichment-site prediction algorithm developed for chromatin immunoprecipitation on chip experiments. BMC Bioinformatics (2006) 1.20
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer (2007) 1.15
NF-Y coassociates with FOS at promoters, enhancers, repetitive elements, and inactive chromatin regions, and is stereo-positioned with growth-controlling transcription factors. Genome Res (2013) 1.15
MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis. Clin Endocrinol (Oxf) (2009) 1.15